Real-world data reveals outcomes of tucatinib combo after T-DXd in advanced breast cancer
NCT ID NCT06961331
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at medical records of 86 people with HER2+ metastatic breast cancer to see how well a combination of tucatinib, trastuzumab, and capecitabine worked after they had already received a treatment called T-DXd. The goal was to measure things like time until the next treatment or death. The study did not give any new treatment but instead analyzed existing data to understand real-world outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
86 people
The number who actually took part.
- Started
-
May 2025
- Finished
-
Sep 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study will include participants in the US Flatiron Dataset diagnosed with HER2+ mBC treated with the tucatinib triplet in the post-T-DXd setting.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. mBC diagnosis between January 1, 2017 and 6 months prior to database cutoff 2. Evidence of human epidermal growth factor receptor 2 (HER2) receptor positivity prior to or up to 90 days following the mBC diagnosis date 3. At least 18 years old on the mBC diagnosis date 4. Treated with systemic anticancer treatment in the metastatic setting, i.e., post mBC diagnosis. 5. Treated with T-DXd in the 1L or 2L or 3L setting, followed immediately by the tucatinib triplet, and at least 1 additional prior HER2-targeted regimen Exclusion Criteria: Patients meeting any of the following criteria will not be included in the study: 1. Patients with evidence of other cancers six months prior to the mBC diagnosis date will be identified with the following International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) codes in all databases: 140.xx - 195.xx, 200.xx - 208.xx, C00.xx - C76.xx, C81.xx - C96.xx. (exclude - ICD-9: 174.X, 175.X; ICD-10: C50.XX) 2. Patients treated with tucatinib prior to T-DXd 3. Patients participating in clinical trials 4. Patients receiving concomitant endocrine therapy on index line
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metastatic HER2+ advanced breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
New York, New York, 10001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.